Profiel
Robert Nowinski is the founder of ContraFect Corp., which was founded in 2008.
He held the title of Chief Executive Officer & Director from 2012 to 2013.
Dr. Nowinski's former jobs include Director at New York Biotechnology Association, Inc., Assistant Professor at the University of Wisconsin, and Associate Professor at Fred Hutchinson Cancer Research Center.
Eerdere bekende functies van Robert Nowinski
| Bedrijven | Functie | Einde |
|---|---|---|
| CONTRAFECT CORPORATION | Algemeen Directeur | 21-11-2013 |
New York Biotechnology Association, Inc.
New York Biotechnology Association, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as an association that promotes the biotechnology industry | Directeur/Bestuurslid | - |
Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center Miscellaneous Commercial ServicesCommercial Services Provides research and testing services | Corporate Officer/Principal | - |
University of Wisconsin
University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
University of Wisconsin
University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center Miscellaneous Commercial ServicesCommercial Services Provides research and testing services | Commercial Services |
New York Biotechnology Association, Inc.
New York Biotechnology Association, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as an association that promotes the biotechnology industry | Commercial Services |
ContraFect Corp.
ContraFect Corp. BiotechnologyHealth Technology Engages in discovery and development of direct lytic agents for life-threatening & drug-resistant infectious diseases | Health Technology |
















